Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E60.76 EPS (ttm)2.31 Insider Own0.10% Shs Outstand224.53M Perf Week-0.70%
Market Cap31.49B Forward P/E19.67 EPS next Y7.13 Insider Trans- Shs Float222.25M Perf Month-1.81%
Income521.80M PEG3.21 EPS next Q1.32 Inst Own97.20% Short Float2.49% Perf Quarter8.03%
Sales3.41B P/S9.23 EPS this Y162.90% Inst Trans-0.10% Short Ratio3.57 Perf Half Y18.13%
Book/sh39.62 P/B3.54 EPS next Y27.26% ROA3.90% Target Price163.45 Perf Year15.58%
Cash/sh6.43 P/C21.81 EPS next 5Y18.91% ROE6.00% 52W Range96.18 - 149.34 Perf YTD14.62%
Dividend- P/FCF35.58 EPS past 5Y14.00% ROI4.20% 52W High-6.16% Beta1.28
Dividend %- Quick Ratio2.80 Sales past 5Y31.50% Gross Margin91.50% 52W Low45.71% ATR3.12
Employees3121 Current Ratio3.30 Sales Q/Q-37.30% Oper. Margin21.80% RSI (14)47.00 Volatility2.24% 2.00%
OptionableYes Debt/Eq0.33 EPS Q/Q-21.80% Profit Margin15.30% Rel Volume0.68 Prev Close140.24
ShortableYes LT Debt/Eq0.32 EarningsOct 26 BMO Payout0.00% Avg Volume1.55M Price140.14
Recom1.90 SMA20-0.94% SMA50-0.17% SMA2009.47% Volume707,842 Change-0.07%
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Oct-19-17 08:16AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : October 19, 2017 Capital Cube
Oct-18-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Oct-16-17 07:17PM  With An ROE Of 6.11%, Has Alexion Pharmaceuticals Incs (ALXN) Management Done A Good Job? Simply Wall St.
Oct-13-17 10:50PM  ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) Business Wire
12:01PM  Is It Too Late To Buy Facebook? Investor's Business Daily
Oct-11-17 03:00AM  Alexion Pharmaceuticals Trying To Close In On Key Technical Measure Investor's Business Daily
Oct-10-17 10:00AM  Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017 Business Wire
Oct-09-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Oct-06-17 10:50PM  ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN) PR Newswire
Oct-05-17 07:39AM  How Strensiq Could Boost Alexions Long-Term Growth Market Realist
Oct-04-17 10:39AM  Gauging Alexions 2018 Growth with Soliris Market Realist
09:11AM  How Is Alexion Pharmaceuticals Positioned after 1H17? Market Realist
07:44AM  Alexion on the Street: Analyst Recommendations in October Market Realist
Oct-03-17 08:14AM  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO Zacks
Oct-02-17 11:14AM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : October 2, 2017 Capital Cube
09:11AM  3 Biotech and Pharma Stocks with Key FDA Catalysts this October Zacks
08:20AM  Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna Forbes
Sep-29-17 10:50PM  ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) Business Wire
09:22AM  When Should You Sell Alexion Pharmaceuticals Inc (ALXN)? Simply Wall St.
08:15AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : September 29, 2017 Capital Cube
Sep-27-17 08:04AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
03:00AM  Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating Investor's Business Daily
03:00AM  Stocks Flashing Renewed Technical Strength: Innoviva Investor's Business Daily
03:00AM  Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-26-17 02:56PM  Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Lawsuit Business Wire
10:24AM  Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal Zacks
09:32AM  3 Biotech Stocks With Major Catalysts in October Motley Fool
08:04AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
03:00AM  Acorda Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Sep-25-17 10:49AM  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer Zacks
Sep-22-17 10:41AM  The Medicines Co. Continues to Focus on Pipeline Development Zacks
08:32AM  Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher Zacks
08:25AM  Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day Zacks
Sep-21-17 11:01AM  Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up Zacks
10:55AM  Karyopharm's Liposarcoma Candidate Superior in Phase II Study Zacks
08:56AM  Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session Zacks
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Sep-20-17 02:32PM  Novartis Poised to Grow on Oncology Portfolio & Biosimilars Zacks
02:10PM  ProQR's Genetic Disorder Candidate Gets Orphan Drug Status Zacks
10:36AM  Teva/Nuvelution to Speed Up Development of Austedo in US Zacks
08:04AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Sep-19-17 10:37AM  Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks
10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
08:51AM  Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher Zacks
08:35AM  Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2% Zacks
07:01AM  Apple Leads 7 Top Stocks Holding In Buy Range Investor's Business Daily
Sep-18-17 02:16PM  RBC Capital's Marc Harris breaks down his best biotech pi... CNBC Videos
10:23AM  Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU Zacks
08:48AM  Why Alexion Pharmaceuticals (ALXN) Could Beat Earnings Estimates Again Zacks
08:43AM  Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 8.6% Higher Zacks
08:39AM  Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9% Zacks
08:35AM  Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher Zacks
Sep-14-17 04:52PM  RBC Launches Biotech Sector Coverage Amid 'An Innovation Revolution' Barrons.com
04:30PM  Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors Business Wire
11:25AM  Glaxo's Shingles Candidate Gets Positive FDA Committee Vote Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
Sep-13-17 06:08PM  Roche (RHHBY) Announces Data on Respiratory Drug Esbriet Zacks
06:02PM  Alexion to Restructure Operations, to Lower Headcount by 20% Zacks
06:00PM  Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis Business Wire
08:33AM  Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data Zacks
12:35AM  [$$] Alexion to Cut Workforce by 20%, Shift Headquarters to Boston The Wall Street Journal
Sep-12-17 04:56PM  Alexion Could Target Sage, Ra Pharma: Analyst TheStreet.com
04:25PM  Alexion Pharmaceuticals is moving its headquarters to Boston Associated Press
04:09PM  Alexion Will Trim Workforce By 20% To Invest In Research Investor's Business Daily
01:05PM  [$$] Alexion to Cut Workforce by 20%, Move Headquarters to Boston The Wall Street Journal
12:55PM  Alexion to close Lexington facility as part of Boston HQ move American City Business Journals
12:34PM  Rare disease drugmaker Alexion to move headquarters to Boston American City Business Journals
11:37AM  Alexion Pharma to lay off 20 pct of workforce Reuters
11:25AM  AstraZeneca's Asthma Candidate Shows Promising Results Zacks
09:35AM  Alexion Pharmaceuticals Slashes 20% of Its Workforce So It Could Boost Profits TheStreet.com
09:09AM  Alexion Pharmaceuticals Inc. moving headquarters to Boston. Associated Press
08:27AM  Alexion to fire 20% of global workforce in restructuring MarketWatch
08:26AM  Drugmaker Alexion to cut 20 pct of jobs Reuters
08:05AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
08:00AM  Alexion Announces Restructuring to Advance Corporate Strategy Business Wire
Sep-11-17 04:15PM  Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017 Business Wire
03:17PM  AstraZeneca's Lung Cancer Study Data Promising, Shares Spike Zacks
02:15PM  Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints Zacks
10:10AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
09:33AM  5 Top-Ranked Biotech Stocks to Buy Right Now Zacks
09:21AM  Your Easy Guide To Credit Suisse's New Top Stocks List Benzinga
Sep-08-17 04:32PM  Why The Biotech 'Catch-Up Rally' Could Add Another 15%-20% Investor's Business Daily
10:24AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
09:54AM  Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth Zacks
Sep-07-17 09:41AM  Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan Zacks
Sep-06-17 06:14PM  ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA Zacks
08:36AM  Cellect Biotechnology (APOP) Soars: Stock Adds 10.2% in Session Zacks
07:37AM  Behind Bioverativs Analyst Recommendations This September Market Realist
Sep-05-17 12:31PM  Sarepta: Time to Buy? Barrons.com
11:50AM  Alexion: Quite a Comeback Barrons.com
11:00AM  Alexion Pharma Stock A Buy After A Pair Of 'De-Risking' Events In 2017 Benzinga
10:00AM  Alexion to Present at Upcoming Investor Conferences Business Wire
09:56AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences Zacks
Sep-01-17 12:09PM  Sell In May And Go Away? Doing So With These Stocks Was A Mistake Benzinga
07:35AM  5 Winning Stocks to Beat September Blues Zacks
Aug-31-17 11:15AM  Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia Zacks
10:36AM  Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion Zacks
Aug-30-17 11:10AM  BioMarin's Pegvaliase BLA Granted Priority Review by the FDA Zacks
Aug-29-17 05:46PM  Advanced Accelerator Gets Action Date for Lutathera from FDA Zacks
04:14PM  Analysts Recommendations for Pfizer in August 2017 Market Realist
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wagner Heidi LSVP, Global Government AffairsOct 02Sale140.0012016,80033,290Oct 04 05:25 PM
Veneman Ann MDirectorSep 05Sale145.81835121,7515,480Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsSep 05Sale146.003,763549,38122,329Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 31Sale142.0061286,90426,092Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 28Sale140.0011,1601,562,40026,704Aug 30 06:13 PM
Veneman Ann MDirectorJul 31Sale137.7470096,4186,315Aug 02 05:18 PM
BAKER BROS. ADVISORS LPDirectorJun 15Buy117.33656,38777,012,4917,645,906Jun 16 04:04 PM
COUGHLIN CHRISTOPHER JDirectorJun 15Buy117.102,000234,2006,333Jun 16 04:55 PM
PARVEN ALVIN SDirectorJun 15Sale116.7883597,5117,568Jun 16 04:54 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy116.321,348,955156,915,4447,317,906Jun 16 04:03 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy118.004,392518,2567,321,850Jun 16 04:04 PM
HANTSON LUDWIGCEOJun 14Buy116.7210,0001,167,20038,725Jun 19 05:21 PM
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM